Adekunle Sanyaolu

Prof. Adekunle Sanyaolu

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2020 in SN Comprehensive Clinical Medicine
Verified
Journal Article
Open access
PDF file
Adekunle SanyaoluAdekunle Sanyaolu
Adekunle Sanyaolu
COChuku Okorie
Chuku Okorie
AMAleksandra Marinkovic
Aleksandra Marinkovic
RPRisha Patidar
Risha Patidar
KYKokab Younis
Kokab Younis
MAMohsin Altaf
Mohsin Altaf
A novel human coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was identified in Wuhan, China, in December 2019. Since then, the virus has made its way across the globe to affect over 180 countries. SARS-CoV-2 has infected humans in all age groups, of all ethnicities, both males and females while spreading through communities at an alarming rate. Given the nature of this virus, there is much still to be learned; however, we know that the clinical manifestations range from a common cold to more severe diseases such as bronchitis, pneumonia, severe acute respiratory distress syndrome (ARDS), multi-organ failure, and even death. It is believed that COVID-19, in those with underlying health conditions or comorbidities, has an increasingly rapid and severe progression, often leading to death. This paper examined the comorbid conditions, the progression of the disease, and mortality rates in patients of all ages, infected with the ongoing COVID-19 disease. An electronic literature review search was performed, and applicable data was then collected from peer-reviewed articles published from January to April 20, 2020. From what is known at the moment, patients with COVID-19 disease who have comorbidities, such as hypertension or diabetes mellitus, are more likely to develop a more severe course and progression of the disease. Furthermore, older patients, especially those 65 years old and above who have comorbidities and are infected, have an increased admission rate into the intensive care unit (ICU) and mortality from the COVID-19 disease. Patients with comorbidities should take all necessary precautions to avoid getting infected with SARS CoV-2, as they usually have the worst prognosis.

1 January 2019 in Global Pediatric Health
Verified
Journal Article
Open access
Adekunle SanyaoluAdekunle Sanyaolu
Adekunle Sanyaolu
COChuku Okorie
Chuku Okorie
XQXiaohua Qi
Xiaohua Qi
JLJennifer Locke
Jennifer Locke
SRSaif Rehman
Saif Rehman
Childhood and adolescent obesity have reached epidemic levels in the United States. Currently, about 17% of US children are presenting with obesity. Obesity can affect all aspects of the children including their psychological as well as cardiovascular health; also, their overall physical health is affected. The association between obesity and other conditions makes it a public health concern for children and adolescents. Due to the increase in the prevalence of obesity among children, a variety of research studies have been conducted to discover what associations and risk factors increase the probability that a child will present with obesity. While a complete picture of all the risk factors associated with obesity remains elusive, the combination of diet, exercise, physiological factors, and psychological factors is important in the control and prevention of childhood obesity; thus, all researchers agree that prevention is the key strategy for controlling the current problem. Primary prevention methods are aimed at educating the child and family, as well as encouraging appropriate diet and exercise from a young age through adulthood, while secondary prevention is targeted at lessening the effect of childhood obesity to prevent the child from continuing the unhealthy habits and obesity into adulthood. A combination of both primary and secondary prevention is necessary to achieve the best results. This review article highlights the health implications including physiological and psychological factors comorbidities, as well as the epidemiology, risk factors, prevention, and control of childhood and adolescent obesity in the United States.

1 July 2013 in Pathogens and Global Health
Verified
Journal Article
Closed access
PBPeter Babokhov
Peter Babokhov
Adekunle SanyaoluAdekunle Sanyaolu
Adekunle Sanyaolu
WOWellington Aghoghovwia Oyibo
Wellington Aghoghovwia Oyibo
AFAdetayo F. Fagbenro-Beyioku
Adetayo F. Fagbenro-Beyioku
NINnaemeka C. Iriemenam
Nnaemeka C. Iriemenam
Despite the recent advances in drug research, finding a safe, effective, and easy to use chemotherapy for human African trypanosomiasis (HAT) remains a challenging task. The four current anti-trypanosomiasis drugs have major disadvantages that limit more widespread use of these drugs in the endemic regions of sub-Saharan Africa. Pentamidine and suramin are limited by their effectiveness against the only first stage of Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense, respectively. In addition, melarsoprol and eflornithine (two second stage drugs) each have disadvantages of their own. The former is toxic and has increasing treatment failures while the latter is expensive, laborious to administer, and lacks efficacy against T. b. rhodesiense. Furthermore, melarsoprol's toxicity and decreasing efficacy are glaring problems and phasing out the drug as a frontline treatment against T. b. gambiense is now possible with the emergence of competent, safe combination chemotherapies such as nifurtimox-eflornithine combination treatment (NECT). The future of eflornithine, on the other hand, is more promising. The drug is useful in the context of combination chemotherapy and potential orally administered analogues. Due to the limits of monotherapies, greater emphasis should be placed on the research and development of combination chemotherapies, based on the successful clinical tests with NECT and its current use as a frontline anti-trypanosomiasis treatment. This review discussed the current and future chemotherapy strategies for the treatment of HAT.

1 January 2022 in Infection & Chemotherapy
Verified
Journal Article
Open access
Adekunle SanyaoluAdekunle Sanyaolu
Adekunle Sanyaolu
COChuku Okorie
Chuku Okorie
AMAleksandra Marinkovic
Aleksandra Marinkovic
AAAbu Fahad Abbasi
Abu Fahad Abbasi
SPStephanie Prakash
Stephanie Prakash
JCJennifer Chan
Jennifer Chan
Sanyaolu A, et al. Infect Chemother. 2022 Jun;54:e44. https://doi.org/10.3947/ic.2022.0008

1 January 2021 in Therapeutic Advances in Infectious Disease
Verified
Journal Article
Open access
PDF file
Adekunle SanyaoluAdekunle Sanyaolu
Adekunle Sanyaolu
COChuku Okorie
Chuku Okorie
AMAleksandra Marinkovic
Aleksandra Marinkovic
NHNafees Haider
Nafees Haider
AAAbu Fahad Abbasi
Abu Fahad Abbasi
VBVyshnavy Balendra
Vyshnavy Balendra
Since emerging from Wuhan, China, in December of 2019, the coronavirus (SARS-CoV-2) has been causing devastating severe respiratory infections in humans worldwide. With the disease spreading faster than the medical community could contain it, death tolls increased at an alarming rate worldwide, causing the World Health Organization to officially sanction the SARS-CoV-2 outbreak as a pandemic, leading to a state of worldwide lockdown for the majority of the year 2020. There have been reports of new strains of the virus emerging in various parts of the world, with some strains displaying even greater infectivity and transmissibility. Areas of the emerging variant of concern arise from countries like the United Kingdom, South Africa, Brazil, and India. These mutations carry a lineage from N501Y, D614G, N439K, Y453F, and others, which are globally dominated by clades 20A, 20B, and 20C. This literature review intends to identify and report SARS-CoV-2 variants that are currently evolving and their disease implications.

1 March 2010 in Parasitology International
Verified
Journal Article
Closed access
NINnaemeka C. Iriemenam
Nnaemeka C. Iriemenam
Adekunle SanyaoluAdekunle Sanyaolu
Adekunle Sanyaolu
WOWellington Aghoghovwia Oyibo
Wellington Aghoghovwia Oyibo
AFAdetayo F. Fagbenro-Beyioku
Adetayo F. Fagbenro-Beyioku